Univest
Univest
  • Markets

Brooks Laboratories (BROOKS) Share Price Rises 8.91% to Rs 69.95 as Market Cap Reaches Rs 189.20 Crore

  • September 11, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Brooks Laboratories Share Price
Brooks Laboratories Ltd. (BROOKS) share price rose to Rs 69.95 today, up 8.91% from the previous close. Market cap was Rs 189.2 crore.

Brooks Laboratories Share Price was at Rs 69.95 as of 2:07 PM IST on 16 November 2026, a gain of Rs 5.72 or 8.91% over the previous close of Rs 64.23. The company has a market capitalisation of Rs 189.20 crore. This Brooks Laboratories stock news update sets out what the price data shows, how the fundamentals look and where the stock sits against its sector and listed peers.

Univest figures confirm the price action, but they do not point to a specific company trigger. This report therefore sticks to verified numbers: the intraday range, valuation ratios and the benchmark of 205 companies in the Pharmaceuticals and Drugs industry. Readers following Brooks Laboratories Share Price Today can treat those figures as a reference point for the Brooks Laboratories share price rise on the Indian stock market.

Table of Contents

Toggle
  • Brooks Laboratories Share Price Today: Price Action Analysis
  • Brooks Laboratories Ltd. (BROOKS) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching Brooks Laboratories
  • About Brooks Laboratories
  • Frequently Asked Questions
    • Why is the Brooks Laboratories share price rising today?
    • What is the market capitalisation of Brooks Laboratories?
    • What are the ROE and ROCE of Brooks Laboratories?
    • How does the Brooks Laboratories P/E ratio compare with the sector?
    • What are the EPS, book value and dividend yield of Brooks Laboratories?
    • How does Brooks Laboratories compare with its listed peers?
    • What is the Brooks Laboratories share price range today?
  • Track Brooks Laboratories Share Price on Univest

Brooks Laboratories Share Price Today: Price Action Analysis

Metric Value
Current Price Rs 69.95
Previous Close Rs 64.23
Today's Move Rs 5.72 (+8.91%)
Open Rs 70.99
High Rs 72.45
Low Rs 65.51
Market Capitalisation Rs 189.2 crore
Market Cap Category Micro Cap

On the fundamental side, the latest Univest figures show a P/E ratio of 2.60, a P/B ratio of 1.00, an EPS of 24.73, ROE of 22.27% and ROCE of 21.72%. Investors can monitor how the Brooks Laboratories Share Price behaves inside today’s range of Rs 65.51 to Rs 72.45 and how those ratios compare with peers in the sections below.

Brooks Laboratories Ltd. (BROOKS) rose to Rs 69.95 from the previous close of Rs 64.23, a move of Rs 5.72 or 8.91%. The stock opened at Rs 70.99, reached a high of Rs 72.45, recorded a low of Rs 65.51.

Brooks Laboratories Share Price Today stands at Rs 69.95, up Rs 5.72 or 8.91% from the previous close of Rs 64.23. The stock opened at Rs 70.99 and has moved between Rs 65.51 and Rs 72.45 so far, while the market capitalisation is Rs 189.20 crore.

The session began with the stock opening at Rs 70.99, which is Rs 6.76 above the previous close. It then touched a low of Rs 65.51, still Rs 1.28 above the previous close, before reaching a high of Rs 72.45, which is Rs 8.22 above it. That gives an intraday range of Rs 6.94 for the Brooks Laboratories Share Price Update.

At Rs 69.95, the stock is Rs 2.50 below the day’s high and Rs 4.44 above the day’s low, so the latest price sits in the upper part of the range. The Brooks Laboratories Share Price Live reading can still change as trading continues, and the day change of Rs 5.72 reflects the latest traded level only.

With the price action laid out, the next section turns to the fundamentals behind this Brooks Laboratories stock analysis.

Brooks Laboratories Ltd. (BROOKS) Fundamental Analysis

Metric Value
Market Capitalisation Rs 189.2 crore
P/E Ratio 2.6x
P/B Ratio 1x
ROE 22.27%
ROCE 21.72%
EPS Rs 24.73
Book Value Per Share Rs 63.98
Dividend Yield 0%

Brooks Laboratories Ltd. (BROOKS) fundamental metrics show P/E 2.6x, P/B 1x, ROE 22.27%, ROCE 21.72%. Taken on their own, these numbers offer context rather than a trading signal.

Brooks Laboratories Ltd. has a market capitalisation of Rs 189.2 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 2.6x, P/B at 1x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 22.27% and ROCE of 21.72%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 24.73, book value per share of Rs 63.98, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.93x, median ROE of 10.98%, median ROCE of 12.63%. They set out the fundamental picture and are not a rating on the stock.

Sector and Industry Context

Metric Value
Sector Healthcare
Industry Pharmaceuticals & Drugs
Benchmark Scope same industry
Company P/E Ratio 2.6x
Benchmark Median P/E 30.93x
Benchmark Average P/E 52.22x
Benchmark P/E Range 2.6x to 1,177x
Company P/B Ratio 1x
Benchmark Median P/B 2.9x
Company ROE 22.27%
Benchmark Median ROE 10.98%
Company ROCE 21.72%
Benchmark Median ROCE 12.63%
Company Market Capitalisation Rs 189.2 crore
Benchmark Median Market Cap Rs 698.04 crore

Brooks Laboratories Ltd. (BROOKS) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

Brooks Laboratories Ltd. (BROOKS) has a P/E ratio of 2.6x, which is below the benchmark median of 30.93x, a difference of -91.59%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Brooks Laboratories Ltd. (BROOKS) has a ROE of 22.27%, which is above the benchmark median of 10.98%, a difference of +102.82%. Brooks Laboratories Ltd. (BROOKS) has a ROCE of 21.72%, which is above the benchmark median of 12.63%, a difference of +71.97%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Sun Pharmaceutical Industries Ltd. SUNPHARMA 4,51,290.91 41.15 5.05 14.85 19.11
Divi's Laboratories Ltd. DIVISLAB 3,05,014.11 90.7 16.95 16.19 21.51
Torrent Pharmaceuticals Ltd. TORNTPHARM 1,77,333.2 83.49 9.65 26.76 19.27
Laurus Labs Ltd. LAURUSLABS 1,30,755.56 97.59 21.57 18.31 18.2
Zydus Lifesciences Ltd. ZYDUSLIFE 1,18,802.71 28.42 4.27 19.69 21.39

Brooks Laboratories Ltd. (BROOKS) has a P/E ratio of 2.6x compared with the displayed peer median of 83.49x. The comparison is relative and should not be read as a recommendation. Its ROE of 22.27% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 21.72% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Brooks Laboratories Ltd. (BROOKS) has a market capitalisation of Rs 189.2 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching Brooks Laboratories

  • Verified price action: the latest Univest figures record a same-day price rise of 8.91%.
  • Valuation: a P/E ratio of 2.60 and a P/B ratio of 1.00 sit below the benchmark medians of 30.93 and 2.90.
  • Returns: ROE of 22.27% and ROCE of 21.72% are above the benchmark medians of 10.98% and 12.63%.
  • Earnings per share: an EPS of 24.73 against a book value of Rs 63.98 per share.
  • Peer position: the lowest P/E and P/B and the highest ROCE among the six companies compared.

About Brooks Laboratories

Brooks Laboratories is a listed company classified in the Healthcare sector, within the Pharmaceuticals and Drugs industry. Univest groups it with 205 companies of the same industry, a set that includes Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Laurus Labs and Zydus Lifesciences. Brooks Laboratories Company News, live ratios and benchmark positions can be followed together on its Univest stock page.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

Why is the Brooks Laboratories share price rising today?

Ans. Univest figures confirm the price action, but they do not point to a specific company trigger. The verified numbers show a rise of 8.91% from the previous close of Rs 64.23 to Rs 69.95, with a day high of Rs 72.45.

What is the market capitalisation of Brooks Laboratories?

Ans. Brooks Laboratories has a market capitalisation of Rs 189.20 crore. That is below the pharma benchmark median of Rs 698.04 crore and the average of Rs 14,540.61 crore across 204 companies, and market capitalisation shows size, not business quality.

What are the ROE and ROCE of Brooks Laboratories?

Ans. Brooks Laboratories has an ROE of 22.27% and an ROCE of 21.72%. Both sit above the benchmark medians of 10.98% and 12.63%, which means returns on equity and on capital employed are ahead of the industry group.

How does the Brooks Laboratories P/E ratio compare with the sector?

Ans. Brooks Laboratories has a P/E ratio of 2.60. The Pharmaceuticals and Drugs benchmark has a median of 30.93 and an average of 52.22 across 171 companies, so the stock sits at the lowest end of a range running to 1,177.00.

What are the EPS, book value and dividend yield of Brooks Laboratories?

Ans. Brooks Laboratories has an EPS of 24.73 and a book value of Rs 63.98 per share. Its dividend yield is 0%, which reflects no payout relative to the current Brooks Laboratories share price of Rs 69.95.

How does Brooks Laboratories compare with its listed peers?

Ans. Against Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Laurus Labs and Zydus Lifesciences, Brooks Laboratories has the lowest P/E at 2.60 and P/B at 1.00, and an ROCE of 21.72% that is above all five.

What is the Brooks Laboratories share price range today?

Ans. Brooks Laboratories opened at Rs 70.99 and has moved between a low of Rs 65.51 and a high of Rs 72.45 so far. That is an intraday range of Rs 6.94, with the latest price at Rs 69.95.

Track Brooks Laboratories Share Price on Univest

Use Brooks Laboratories Ltd. (BROOKS) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Users can track the live Brooks Laboratories Share Price, fundamental ratios such as P/E, P/B, ROE and ROCE, 52-week levels and wider market insights on Univest. The Univest stock page brings these details together, so changes in price, ratios and benchmark position can be followed in one place while the Indian stock market session continues.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply